Pubblicazione scientifica

Clinicopathological features and outcome of chronic lymphocytic leukaemia in Chinese patients

FILONE TECNOLOGICO	TEMA
trasformazione e commercializzazione	macchinari di ausilio alla lavorazione e trasformazione del pesce

RIASSUNTO

Chronic lymphocytic leukaemia (CLL) is uncommon in Chinese population and its biology, genetics and treatment outcome in Chinese patients have not been comprehensively investigated. In this study, we studied the clinicopathological features and outcome of 212 Chinese patients with newly diagnosed CLL in Hong Kong and Singapore. The median age at diagnosis was 64 years. The majority of patients presented with early-stage disease (Binet stage A, 56.1%). Del(13)(q14) was the most frequent abnormality (41.7%) detected by fluorescence in situ hybridization (FISH) analysis. Del(17p) and TP53 gene mutations were detected in 7.8% and 8.2% of patients, respectively. MYD88 mutations were found at a higher frequency (11.5%) than expected. CLL with unmutated variable region of the immunoglobulin heavy chain genes (IGHV) occurred in only 31.2% of cases, and was associated with advanced-stage disease (p <0.01) and adverse FISH abnormalities (p<0.01). With a median follow-up of 39 months, the median overall survival (OS) was 108 months. The presence of del(17p) or TP53 mutations was associated with a significantly shorter time to first treatment and an inferior OS (p <0.01). Unmutated IGHV was also associated with a significantly shorter time to treatment (p <0.01). Among patients who required treatment, the median OS and progression-free survival (PFS) were 107 and 23 months, respectively. The presence of del(17p) was associated with a significantly inferior OS and PFS (p <0.01). In summary, Chinese CLL patients had similar genetic aberrations at diagnosis compared with those of Western populations. FISH abnormalities are major factors affecting outcome.

DATA

Data di pubblicazione: 09/03/2017

AUTORI

CHAN THOMAS SAU-YAN
LEE YUH-SHAN
GIUDICE ILARIA DEL
MARINELLI MARILISA
ILARI CATERINA
CAFFORIO LUCIANA
GUARINI ANNA
TAN DARYL
PHIPPS COLIN
GOH YEOW-TEE
HWANG WILLIAM
GOH ALLAN ZHI-KAI
SIU LISA LAI-PING
WU SALIANGI
HA CHUN-YIN
LIN SHEK-YING
KWOK CHI-HANG
LAU CHI-KUEN
WONG KIT-FAI
FOA ROBIN
KWONG YOK-LAM
TSE ERIC

ENTE DI AFFERENZA

DEPT MEDICINE UNIV HONG KONG QUEEN MARY HOSPITAL HONG KONG CHINA
DEPT HAEMATOLOGY SINGAPORE GEN HOSPITAL OUTRAM SINGAPORE
DEPT CELLULAR BIOTECHNOLOGIES & HEMATOLOGY SAPIENZA UNIV ROME ITALY
DEPT MOLECULAR MEDICINE SAPIENZA UNIV ROME ITALY
DEPT PATHOLOGY QUEEN ELIZABETH HOSPITAL HONG KONG CHINA
DEPT MEDICINE QUEEN ELIZABETH HOSPITAL HONG KONG CHINA
DEPT MEDICINE TUEN MUN HOSPITAL HONG KONG CHINA
DEPT MEDICINE UNITED CHRISTIAN HOSPITAL HONG KONG CHINA
DEPT MEDICINE PRINCESS MARGARET HOSPITAL HONG KONG CHINA
DEPT MEDICINE TSEUNG KWAN O HOSPITAL HONG KONG CHINA

RIVISTA

Oncotarget, 8(15), 25455-25468

IMPACT FACTOR

3,71

indietro